New drugs and therapies have become indispensable for treating an array of cancers. Unfortunately, they can also cause damage to the heart, a side effect that has led to the development of a new ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

Capricor presented preclinical data at the 2024 American Association of Extracellular Vesicles (AAEV) Annual Meeting ...

WINT Enrolling SCAI Stage C participants in SEISMiC C trial, preparing for Phase 3 readiness Pennsylvania-based Windtree ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Therapeutic strides in biotech are advancing promising candidates in clinic to address different stages of sleep apnea and ...

Cardiol’s focus on anti-inflammatory and anti-fibrotic therapies for heart disease, including its ... comprises the Phase II ...

Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...

Cybin launches Phase 3 trials for CYB003, aiming to offer lasting relief for ... "Just three years after filing an ...

Notably, the successful completion of the FDA End of Phase ... the drug’s favorable cardiac efficacy. This positions Altimmune advantageously against competitors, with no significant safety concerns.

A new clinical study shows that an inhibitor of Fas ligand ... randomised, open-label, controlled, phase 2 trial’ has been published in eClinicalMedicine. The physiological role of FasL is to keep ...